Sameh Gaballa, MD, Moffitt Cancer Center, Tampa, FL, briefly discusses the results of a Phase II single-arm study of obinutuzumab and ibrutinib as frontline treatment for patients with follicular lymphoma (FL) or marginal zone lymphoma (MZL). The safety profile was favorable, and promising outcomes were observed, indicating that this combination therapy holds potential as a chemotherapy-free regimen for newly diagnosed patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.